Literature DB >> 11369668

Clinical correlates of splenic histopathology and splenic karyotype in myelofibrosis with myeloid metaplasia.

R A Mesa1, C Y Li, G Schroeder, A Tefferi.   

Abstract

Splenic extramedullary hematopoiesis is an integral component of myelofibrosis with myeloid metaplasia (MMM) and may be classified into 3 distinct histologic patterns of infiltration by myeloid precursors: diffuse, nodular, and a predominance of immature granulocytes. These 3 histologic patterns occurred in 121 (56.8%), 75 (35.2%), and 17 (8%), respectively, of 213 patients with MMM who underwent splenectomy at a single institution. In general, karyotypic findings in splenic tissue (n = 92) were similar to those seen in the bone marrow. The histologic pattern of immature granulocyte predominance, the presence of microscopic splenic infarcts (26 patients), or the detection of an abnormal splenic karyotype (52 patients) was significantly associated with decreased postsplenectomy survival. These adverse features were also associated with characteristics of advanced disease. These observations support the bone marrow origin of the myeloid progenitor pool in the spleen of patients with MMM and suggest a prognostic value for splenic histopathology and karyotype. (Blood. 2001;97:3665-3667)

Entities:  

Mesh:

Year:  2001        PMID: 11369668     DOI: 10.1182/blood.v97.11.3665

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  Splenic extramedullary hematopoietic proliferation in Philadelphia chromosome-negative myeloproliferative neoplasms: heterogeneous morphology and cytological composition.

Authors:  Sonam Prakash; Ronald Hoffman; Sharon Barouk; Y Lynn Wang; Daniel M Knowles; Attilio Orazi
Journal:  Mod Pathol       Date:  2012-03-02       Impact factor: 7.842

Review 2.  Approach to MPN Symptom Assessment.

Authors:  Holly Geyer; Ruben A Mesa
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

3.  Spleens of myelofibrosis patients contain malignant hematopoietic stem cells.

Authors:  Xiaoli Wang; Sonam Prakash; Min Lu; Joseph Tripodi; Fei Ye; Vesna Najfeld; Yan Li; Myron Schwartz; Rona Weinberg; Paul Roda; Attilio Orazi; Ronald Hoffman
Journal:  J Clin Invest       Date:  2012-11       Impact factor: 14.808

4.  Genomic characterization of spleens in patients with myelofibrosis.

Authors:  Eran Zimran; Joseph Tripodi; Raajit Rampal; Franck Rappoport; Sharon Zirkiev; Ronald Hoffman; Vesna Najfeld
Journal:  Haematologica       Date:  2018-05-10       Impact factor: 9.941

Review 5.  The role of morphology, cytochemistry and immunohistochemistry in the diagnosis of chronic myeloproliferative diseases.

Authors:  Chin-Yang Li
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 6.  The therapy of myelofibrosis: targeting pathogenesis.

Authors:  Ruben A Mesa
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

7.  Histopathology of spleen allograft rejection in miniature swine.

Authors:  Frank J M F Dor; Bernd Gollackner; Kenji Kuwaki; Dicken S C Ko; David K C Cooper; Stuart L Houser
Journal:  Int J Exp Pathol       Date:  2005-02       Impact factor: 1.925

Review 8.  Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia.

Authors:  Ruben A Mesa; Alfonso Quintás-Cardama; Srdan Verstovsek
Journal:  Curr Hematol Malig Rep       Date:  2007-02       Impact factor: 4.213

9.  Extramedullary hematopoiesis in the absence of myeloproliferative neoplasm: Mayo Clinic case series of 309 patients.

Authors:  N Fan; S Lavu; C A Hanson; A Tefferi
Journal:  Blood Cancer J       Date:  2018-11-19       Impact factor: 11.037

Review 10.  Extramedullary Hematopoiesis of the Liver and Spleen.

Authors:  Diana Cenariu; Sabina Iluta; Alina-Andreea Zimta; Bobe Petrushev; Liren Qian; Noemi Dirzu; Ciprian Tomuleasa; Horia Bumbea; Florin Zaharie
Journal:  J Clin Med       Date:  2021-12-13       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.